Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 6/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10313118 | 0.88 | NAMPT (0.40) | MIFP2RX7NOTUM | |
| SCHEMBL10313039 | 0.83 | F10 (0.44) | F10 | |
| SCHEMBL1098231 | 0.82 | F10 (0.54) | F10ABCB11F2ST14MIF | |
| SCHEMBL13886965 | 0.81 | NAMPT (0.40) | MIFNOTUM | |
| SCHEMBL13886815 | 0.76 | P2RX7 (0.51) | MIFP2RX7NOTUM | |
| SCHEMBL13181164 | 0.75 | MIF (0.39) | MIFNOTUM | |
| SCHEMBL14450639 | 0.73 | MIF (0.42) | F10MIFNOTUM | |
| SCHEMBL14450888 | 0.73 | F10 (0.43) | F10MIFNOTUM | |
| SCHEMBL1097501 | 0.72 | F10 (0.62) | F10ABCB11F2ST14MIF | |
| SCHEMBL14450606 | 0.72 | MIF (0.41) | MIFNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | F10 8/4885ABCB11 223/4885F2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.